[Behavior of serum triglycerides, cholesterol, uric acid and sugar levels and of thrombocyte function in heart infarct patients during a 2-year therapy with acetylsalicylic acid, placebo or phenprocoumon].
D015110:4-Hydroxycoumarins / Q000627:therapeutic use*; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis*; D001792:Blood Platelets; D002784:Cholesterol / Q000097:blood*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005860:Germany, West; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000517:prevention & control; D010644:Phenprocoumon / Q000627:therapeutic use*; D010919:Placebos; D011446:Prospective Studies; D011897:Random Allocation; D014280:Triglycerides / Q000097:blood*; D014527:Uric Acid / Q000097:blood*
D015110:4-Hydroxycoumarins; D001786:Blood Glucose; D010919:Placebos; D014280:Triglycerides; D014527:Uric Acid; D002784:Cholesterol; D010644:Phenprocoumon; D001241:Aspirin
Verhalten der Serumspiegel von Triglyceriden, Cholesterin, Harnsäure und Blutzucker sowie der Thrombozytenfunktion bei Herzinfarktpatienten während einer 2jährigen Therapie mit Acetylsalicylsäure, Placebo oder Phenprocoumon.